The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 22, 2022
Filed:
Jan. 31, 2019
Applicant:
Teva Pharmaceuticals Australia Pty Ltd, Macquarie Park, AU;
Inventors:
Sarah L. Pogue, North Wales, PA (US);
David S. Wilson, North Wales, PA (US);
Anthony Gerard Doyle, Drummoyne, AU;
Collette Jane Behrens, Macquarie Park, AU;
Assignee:
Teva Pharmaceuticals Australia Pty Ltd., Macquarie Park, AU;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/454 (2006.01); C07K 16/30 (2006.01); A61K 38/21 (2006.01); C07K 14/56 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 31/454 (2013.01); A61K 38/212 (2013.01); A61K 45/06 (2013.01); A61K 47/6813 (2017.08); A61K 47/6867 (2017.08); C07K 14/56 (2013.01); C07K 16/28 (2013.01); C07K 16/2896 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2319/035 (2013.01); C07K 2319/33 (2013.01);
Abstract
Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.